An ongoing trial, BrainChild-01 by Vitanza et al [24], reported promising phase I data on HER2 targeting CAR-T therapy in relapsed/refractory CNS tumours like gliomas in the pediatric/young adult population. This evidence concerns the gene ERBB2 and central nervous system cancer.